

*Cancer immunology
makes it to clinic:
how cancer
will be treated
in the coming years*

AUDITORIUM USI – UNIVERSITÀ DELLA SVIZZERA ITALIANA
LUGANO, SWITZERLAND • **SEPTEMBER 26, 2015**



IBSA FOUNDATION
for scientific research



IOR

Institute of Oncology Research



Università
della
Svizzera
italiana

Institute for
Research in
Biomedicine



SPEAKERS & CHAIRMEN



Andrea Alimonti SWITZERLAND (ERC Investigator, Head Molecular Oncology at Institute of Oncology Research, IOR, of the Oncology Institute of Southern Switzerland, IOSI)

Carlo Catapano SWITZERLAND (Director of Institute of Oncology Research, IOR, Oncology Institute of Southern Switzerland, IOSI, Bellinzona)

Franco Cavalli SWITZERLAND (Professor of Oncology. Scientific Director of Institute of Oncology Institute of Southern Switzerland, IOSI, Bellinzona)

Johann De Bono UK (Head of the Division of Clinical Studies. Director of the London Centre of Excellence and Director of the Drug Development Unit at the Institute of Cancer Research and The Royal Marsden Hospital, London)

Michael Detmar SWITZERLAND (Professor of Pharmacogenomics at the Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH, Zurich)

Jesus Gil UK (Head of the Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College Faculty of Medicine, London)

Fabio Grassi SWITZERLAND (T Cell Development Group Leader Institute for Research in Biomedicine, Bellinzona)

Douglas Hanahan SWITZERLAND (Director of the Swiss Institute for Experimental Cancer Research, ISREC, at the Swiss Federal Institute of Technology, EPFL, Lausanne)

Wilhelm Krek SWITZERLAND (Chairman of the Institute of Molecular Health Sciences at ETH Zurich, and of the Laboratory of Cell Signaling and Disease Biology. Chairman of the Center for Metabolic Diseases, ETH and University-Hospital, Zurich)

Antonio Lanzavecchia SWITZERLAND (Professor of Human Immunology at ETH, Zurich. Director of the Institute for Research in Biomedicine, IRB, Bellinzona)

Alberto Mantovani ITALY (Professor at Humanitas University. Scientific Director of the Clinical Institute Humanitas IRCCS, Milan)

Massimiliano Mazzone BELGIUM (Professor of Translational Oncology. Head of the Lab of Molecular Oncology and Angiogenesis VIB Vesalius Research Center, University of Leuven)

Giuseppe Opocher ITALY (Scientific Director, Associate Professor of Endocrinology. Head of "SSD Tumori Ereditari e Endocrinologia Oncologica", Oncology Institute Veneto & Department of Medicine DIMED, University of Padua)

Pier Paolo Pandolfi USA (Director of the Cancer Center and Cancer Research Institute George C. Reisman. Professor of Medicine and Pathology, Harvard Medical School Beth Israel Deaconess Medical Center, Boston)

Federica Sallusto SWITZERLAND (Cellular Immunology Group Leader Institute for Research in Biomedicine, Bellinzona)

Mark J. Smyth AUSTRALIA (PhD, FAHMS Senior Scientist & Immunology Coordinator NH&MRC SPRF QIMR Berghofer Medical Research Institute, Brisbane)

SCIENTIFIC COMMITTEE



Andrea Alimonti (ERC Investigator, Head Molecular Oncology at IOR/IOSI)

Silvia Misiti (Director of IBSA Foundation)

Giuseppe Zizzo (Secretary of IBSA Foundation)

PROGRAM



09:00 **Welcome of IBSA Foundation** Silvia Misiti

Introduction to Forum Andrea Alimonti

SESSION I

Chairmen: **Carlo Catapano** and **Fabio Grassi**

09:15 **Pier Paolo Pandolfi** The Tumor Immune Landscaping Project
and the Co-Clinical Platform

09:45 **Antonio Lanzavecchia** In depth analysis of the human immune response

10:15 **Franco Cavalli** Immunology and lymphomas

10:45 **Michael Detmar** Surprising roles of lymphatic endothelium
in cancer progression and inflammation

11:15 **Coffee break**

11:45 **Jesus Gil** Regulation of the senescence-associated secretory phenotype

12:15 **Andrea Alimonti** Immune-senescence therapy for cancer

12:45 **Johann De Bono** Immunity and prostate cancer

13:15 **Lunch**

SESSION II

Chairmen: **Federica Sallusto** and **Giuseppe Opocher**

14:15 **Douglas Hanahan** Breaking barriers to effective immunotherapy against solid tumors

14:45 **Mark J. Smyth** Immunotherapeutic control of tumor metastasis

15:15 **Massimiliano Mazzone** Heterogeneity of cancer inflammation:
a double edged sword for therapy

15:45 **Wilhelm Krek** Mechanisms of hypoxia signaling in cancer

16:15 **Alberto Mantovani** Inflammation and cancer from bench to bedside

16:45 **Andrea Alimonti** Closing remarks

PRACTICAL INFORMATION



SATURDAY

SEPTEMBER 26, 2015

09:00 > 17:15

Auditorium USI – Università della Svizzera Italiana
via Giuseppe Buffi, 13
Lugano, Switzerland

Registrations will be accepted on first come, first served basis by September 20, 2015, available seats about 200. The working language of the Forum will be English.

Free **pre-registration**, which includes coffee breaks and lunch, is required at: www.ibsafoundation.org

For info:

CG MKT

phone +39 06 30 09 00 20

fax +39 06 30 31 13 03

e-mail info@cgmkt.it

IBSA FOUNDATION
for scientific research

Via del Piano, 29
6915 Pambio-Noranco (CH)
+41 (0) 58 36 01 560

info@ibsafoundation.org
www.ibsafoundation.org

online registration

